ResearchMoz

Computational Biology (Pharmacodynamics, Cellular Modeling, Computational Genomics, Proteomics, Pharmacogenomics, Pharmacokinetics, Human Simulation Software, Drug Discovery & Development) Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018

Transparency Market Research
Published Date » 2013-05-07
No. Of Pages » 112
   
 The computational biology market is predicted to have a notable growth owing to its wide use by biotechnology and pharmaceutical companies to reduce the incidences of late stage failures of their drugs and to thereby curb R&D expenditure. Computational biology is also assisting in reducing the extensive use of humans in trials and is therefore useful for pediatric trials, trials on pregnant women and orphan disease research. 
   
 This report analyses the global market for computational biology by two main types of studies-cellular modeling and disease modeling. Each of these segments has been further analyzed by various studies with use of simulation, right from drug discovery to drug development. The market has also been bifurcated on the basis of tools which include...
Table of Content

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Scope Of The Report
1.4 Research Methodology
1.4.1 Sources
1.4.1.1 Secondary Research
1.4.1.2 Primary Research
1.4.1.3 Models
1.5 Assumptions

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Computational Biology Market (2011 & 2018)
2.2 Global Computational Biology Market, by Types, 2011 (USD Million)

Chapter 3 Global Computational Biology Market Dynamics
3.1 Market Overview
3.2 Drivers
3.2.1 Failure Of Drug Candidates in Late Stage of Clinical Trials
3.2.1.1 Average Cost to Develop One New Drug (1975 -2011) (USD Million)
3.2.1.2 Trend of Rise in Failure of Phase II Clinical Trials (2006- 2012)
3.2.1.3 Reasons For Failure (%) in Phase II & Phase III
3.2.2 Enhanced Computational Tools
3.2.3 Improved Government Funding &Industrial Support
3.3 Restraints
3.3.1 Lack of Standardization
3.3.2 Non-Verified Predictive Models
3.4 Challenges
3.4.1 Shortage of Skilled Resources
3.4.2 Data Storage
3.5 Opportunities
3.5.1 Cloud Computing
3.5.2 Modelling And Simulations in Paediatrics Drug Development
3.6 Porters Five Forces Analysis
3.6.1 Bargaining Power of Suppliers
3.6.2 Bargaining Power of Buyers
3.6.3 Threat of New Entrants
3.6.4 Threat Of Substitutes
3.6.5 Competitive Rivalry
3.7 Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis: Global Computational Biology Market, by Geography
3.8 End User Analysis
3.8.1 End User Analysis: Global Computational Biology Market, 2011 & 2018 (%)

Chapter 4 Global Computational Biology Market, by Applications
4.1 Introduction
4.1.1 Cellular Modelling and Simulation
4.1.1.1 Computational Genomics
4.1.1.1.1 Global Computational Genomics Market Revenues, 2010 – 2018 (USD Million)
4.1.1.2 Computational Proteomics
4.1.1.2.1 Global Computational Proteomics Market Revenues, 2010 – 2018 (USD Million)
4.1.1.3 Pharmacogenomics
4.1.1.3.1 Global Computational Pharmacogenomics Market Revenues, 2010 – 2018 (USD Million)
4.1.1.4 Others (Metabolomics/ Transcriptomics)
4.1.1.4.1 Global Computational Others (Metabolomics/Transcriptomics) Market Revenue, 2010 – 2018 (USD Million)
4.1.2 Disease Modelling And Simulation Applications / CADD (Computer Aided Drug Design)
4.1.2.1 Drug Discovery
4.1.2.1.1 Global Computational Drug Discovery Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2 Target Identification
4.1.2.1.2.1 Global Computational Target Identification Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.3 Target Validation
4.1.2.1.3.1 Global Computational Target Validation Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.4 Lead Identification/Discovery
4.1.2.1.4.1 Global Computational Lead Identification Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.5 Lead Optimization
4.1.2.1.5.1 Global Computational Lead Optimization Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1 Drug Development
4.1.2.1.1 Preclinical
4.1.2.1.1.1 Global Computational Preclinical Trials Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2 Clinical Trials
4.1.2.1.2.1 Global Computational Clinical Trials Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2.2 Phase I
4.1.2.1.2.3 Global Computational Clinical Trials Phase I Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2.4 Phase II
4.1.2.1.2.5 Global Computational Clinical Trials Phase II Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2.6 Phase III
4.1.2.1.2.7 Global Computational Clinical Trials Phase III Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.3 Human Body Simulation Software
4.1.2.1.3.1 Global Computational Human Simulation Software Market Revenues, 2010 – 2018 (USD Million)

Chapter 5 Global Computational Biology Market, by Tools
5.1 Overview
5.2 Database
5.2.1 Global Computational Biology Database Market Revenues, 2010 – 2018 (USD Million)
5.3 IT Infrastructure (Hardware)
5.3.1 Global Computational Biology Hardware Market Revenues, 2010 – 2018 (USD Million)
5.4 Analysis Software & Services
5.4.1 Global Computational Biology Software Market Revenues, 2010 – 2018 (USD Million)

Chapter 6 Global Computational Biology Market, by Services
6.1 Overview
6.2 In-House Computational Biology
6.2.1 Global In-House Computational Biology Market Revenues, 2010 – 2018 (USD Million)
6.3 External/Contract Computational Biology
6.3.1 Global Contract Computational Biology Market Revenues, 2010 – 2018 (USD Million)

Chapter 7 Global Computational Biology Market, by Geography
7.1 Overview
7.2 North America
7.2.1 North America Computational Biology Market Revenues, 2010 – 2018 (USD Million)
7.3 Europe
7.3.1 Europe Computational Biology Market Revenues, 2010 – 2018 (USD Million)
7.4 Asia
7.4.1 Asia Computational Biology Market Revenues, 2010 – 2018 (USD Million)
7.5 ROW
7.5.1 Row Computational Biology Market Revenues, 2010 – 2018 (USD Million)

Chapter 8 Market Share Analysis
8.1 Market Share by Key Players
8.1.1 Global Computational Biology Market Share Analysis of Key Players, 2011 (%)

Chapter 9 Recommendations
9.1 Success Strategies
9.1.1 Rigorous Research and Development (R&D) Initiatives
9.1.2 Investing in Emerging Economies
9.1.3 Investing in High-End Technologies
9.1.4 Collaborations, Mergers and Acquisitions
9.2 Barriers to be Considered
9.2.1 High Cost of Investment

Chapter 10 Company Profiles
10.1 Accelrys
10.1.1 Company Overview
10.1.2 Financial Overview
10.1.3 Product Portfolio And Services
10.1.4 Business Strategy
10.1.5 Recent Developments
10.2 Certara
10.2.1 Company Profile
10.2.2 Financial Overview
10.2.3 Product Portfolio And Services
10.2.4 Business Strategy
10.2.5 Recent Developments
10.3 Chemical Computing Group Inc.
10.3.1 Company Profile
10.3.2 Financial Overview
10.3.3 Product Portfolio
10.3.4 Business Strategy
10.3.5 Recent Developments
10.4 Compugen, Ltd
10.4.1 Company Profile
10.4.2 Financial Overview
10.4.3 Business Strategy
10.4.4 Recent Developments
10.5 Entelos
10.5.1 Company Profile
10.5.2 Financial Overview
10.5.3 Product Portfolio And Services
10.5.4 Business Strategy
10.5.5 Recent Developments
10.6 Genedata AG
10.6.1 Company Profile
10.6.2 Financial Overview
10.6.3 Product Portfolio And Services
10.6.4 Business Strategy
10.6.5 Recent Developments
10.7 Insilico Biotechnology AG
10.7.1 Company Profile
10.7.2 Financial Overview
10.7.3 Product Portfolio
10.7.4 Business Strategy
10.7.5 Recent Developments
10.8 Leadscope, Inc
10.8.1 Company Profile
10.8.2 FinancialOverview
10.8.3 Product Portfolio
10.8.4 Business Strategy
10.8.5 Recent Developments
10.9 Nimbus Discovery LLC
10.9.1 Company Profile
10.9.2 Financial Overview
10.9.3 Product Portfolio
10.9.4 Business Strategy
10.9.5 Recent Developments
10.10 RhenoviaPharma SAS
10.10.1 Company Profile
10.10.2 Financial Overview
10.10.3 Product Portfolio And Services
10.10.4 Business Startegy
10.10.5 Recent Developments
10.11 Schrodinger
10.11.1 Company Overview
10.11.2 Financial Overview
10.11.3 Product Portfolio And Services
10.11.4 Business Strategy
10.11.5 Recent Developments
10.12 Simulation Plus, Inc.
10.12.1 Company Profile
10.12.2 Financial Overview
10.12.3 Product Portfolio And Services
10.12.4 Business Strategy
10.12.5 Recent Developments

List of Tables

List of Tables

TABLE 1 Global Computational Biology Market: Snapshot (2011 & 2018)
TABLE 2 R&D Function by Expenditure (%)
TABLE 3 Global Computational Biology Market Revenues, by Segments, 2010 – 2018 (USD Million)
TABLE 4 Global Cellular Modeling and Biology Simulation Market Revenues, by Types, 2010 – 2018 (USD Million)
TABLE 5 Global Cellular Modeling and Biology Simulation Market Revenues, by Geography, 2010 – 2018 (USD Million)
TABLE 6 Global Disease Modeling and Simulation Market Revenues, by Types, 2010 - 2018 (USD Million)
TABLE 7 Global Disease Modeling and Simulation Market Revenues, by Geography, 2010 - 2018 (USD Million)
TABLE 8 Global Computational Drug Development Market Revenues, by Types, 2010 - 2018 (USD Million)
TABLE 9 Software Packages for PBPK Modeling
TABLE 10 Global Computational Biology Market Revenues, by Tools, 2010- 2018 (USD Million)
TABLE 11 Global Computational Services Market Revenues, by Services, 2010- 2018 (USD Million)
TABLE 12 Global Computational Biology Market, by Geography, 2010- 2018 (USD Million)

List of Figures

List of Figures

FIG. 1 Global Computational Biology: Market Segmentation
FIG. 2 Global Computational Biology Market, By Types, 2011 (USD Million)
FIG. 3 Average Cost to Develop one New Drug (1975 -2011) (USD Million)
FIG. 4 Trend of Rise in Failure of Phase II Clinical Trials (2006- 2012)
FIG. 5 Reasons for Failure (%) in Phase II & Phase III
FIG. 6 Porter’s Five Forces Analysis for Computational Biology Market
FIG. 7 Market Attractiveness Analysis: Global Computational Biology Market, By Geography
FIG. 8 End User Analysis: Global Computational Biology Market, 2011 & 2018 (%)
FIG. 9 Global Computational Genomics Market Revenues, 2010 – 2018 (USD Million)
FIG. 10 Global Computational Proteomics Market Revenues, 2010 – 2018 (USD Million)
FIG. 11 Global Computational Pharmacogenomics Market Revenues, 2010 – 2018 (USD Million)
FIG. 12 Global Computational Others (Metabolomics/ Transcriptomics) Market Revenue, 2010 – 2018 (USD Million)
FIG. 13 Global Computational Drug Discovery Market Revenues, 2010 – 2018 (USD Million)
FIG. 14 Global Computational Target Identification Market Revenues, 2010 – 2018 (USD Million)
FIG. 15 Global Computational Target Validation Market Revenues, 2010 – 2018 (USD Million)
FIG. 16 Global Computational Lead Identification Market Revenues, 2010 – 2018 (USD Million)
FIG. 17 Global Computational Lead Optimization Market Revenues, 2010 – 2018 (USD Million)
FIG. 18 Global Computational Preclinical Trials Market Revenues, 2010 – 2018 (USD Million)
FIG. 19 Global Computational Clinical Trials Market Revenues, 2010 – 2018 (USD Million)
FIG. 20 Global Computational Clinical Trials Phase I Market Revenues, 2010 – 2018 (USD Million)
FIG. 21 Global Computational Clinical Trials Phase II Market Revenues, 2010 – 2018 (USD Million)
FIG. 22 Global Computational Clinical Trials Phase III Market Revenues, 2010 – 2018 (USD Million)
FIG. 23 Global Computational Human Simulation Software Market Revenues, 2010 – 2012 (USD Million)
FIG. 24 Global Computational Biology Database Market Revenues, 2010 – 2018 (USD Million)
FIG. 25 Global Computational Biology Hardware Market Revenues, 2010 – 2018 (USD Million)
FIG. 26 Global Computational Biology Software Market Revenues, 2010 – 2018 (USD Million)
FIG. 27 Global In-House Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 28 Global Contract Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 29 North America Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 30 Europe Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 31 Asia Computational Biology Market Revenue, 2010 – 2018 (USD Million)
FIG. 32 Row Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 33 Global Computational Biology Market Share Analysis Of Key Players, 2011 (%)
FIG. 34 Annual Revenues: Accelrys, 2009 - 2011 (USD Million)
FIG. 35 Annual Revenue: Compugen, 2010 – 2012 (USD Million)
FIG. 36 Annual Revenues: Simulation Plus, Inc., 2010 – 2012 (USD Million)

Upcoming Reports:

Greece: market of napkins and napkin liners for babies
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the napkins and napkin liners for babies market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the napkins and napkin liners for babies market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way,...
Nanomagnetics (Materials and Devices) Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
The global market for nanomagnetics (materials and devices) is largely driven by the demand from the data storage sector. The data storage media is the largest end use segment, followed by diagnostics and biotechnology. Continuous new developments in the field of nanotechnology are expected to fuel the growth of the nonmagnetic market. Geographically, the U.S. is the largest market, but Japan is the fastest growing region due to its extensive work in the field, which has made it the hub for nanotechnology. Nanomagnetics is finding increased applications in medicine such as in drug...
Poland: market of travertine, ecaussine, granite, porphyry, basalt, sandstone
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the travertine, ecaussine, granite, porphyry, basalt, sandstone market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the travertine, ecaussine, granite, porphyry, basalt, sandstone market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

A Health Tech Incubator Started by GE Healthcare
Oct 30, 2014  
For the very first time, a health tech start up campus has been established by GE Healthcare at its headquarters at Helsinki, Finland. This area already has about twenty such healthcare start ups that are working on cloud services, wireless technologies, apps, and sensors that aim at improving healthcare. The main rationale behind such a step is providing opportunities for further...
Net Earnings of DuPont Increases 52% despite Agricultural Turmoil
Oct 29, 2014  
DuPont - The Wilmington, Del-based leading chemical company faced decline of three percent sales to $7.5 billion in the quarter ending of September 30. The company’s third-quarter earnings were increased by 52 percent to $433 million albeit the slow global growth and agricultural downside.   The company witnessed the biggest drags from chemical sales with eight percent...
Appeal for Sanitization in Construction Industry through Government Regulations: CIOB Ghana
Oct 29, 2014  
Rockson Dogbegah - The Chairman of the Chartered Institute of Building Ghana commented that the construction industry needs a thorough cleaning up and assurance of proper growth. Mr. Dogbegah also said that a few factors are extremely important for a proper development in the construction industry. These include keen adherence to standards, supreme sense of professionalism, and sheer pursuance...
Facebook Hints of Rise in Expenses in 2015, Shares Drop
Oct 29, 2014  
Facebook has announced on Tuesday that it is prepping for a dramatic rise in spending in the year 2015. This warning has come combined with a projected slowdown in the company’s revenues after revenues were analyzed at the end of the third quarter of the year. The plans of such hefty spending in the next financial year by the company are indicative of stress in the investor...
Samsung Records Poorest Profits in Q3 2014
Oct 29, 2014  
In the quarter ending September 2014, Samsung Electronics Co. Ltd registered the smallest earnings ever in two years. The drop in earnings can be easily attributed to heavy competition from new Chinese devices and the Apple phones. The net income stood at US$4 billion for the South Korea-based company. Apple has been Samsung’s strongest contender ever since the latter entered the...